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ABSTRACT
Objective To compare the effect of induction of labour
with a policy of expectant monitoring for intrauterine
growth restriction near term.
DesignMulticentre randomised equivalence trial (the
Disproportionate Intrauterine Growth Intervention Trial At
Term (DIGITAT)).
SettingEightacademicand44non-academichospitals in the
Netherlands between November 2004 and November 2008.
Participants Pregnant women who had a singleton
pregnancy beyond 36+0 weeks’ gestation with suspected
intrauterine growth restriction.
Interventions Induction of labour or expectant monitoring.
Main outcome measures The primary outcome was a
composite measure of adverse neonatal outcome,
defined as death before hospital discharge, five minute
Apgar score of less than 7, umbilical artery pH of less than
7.05, or admission to the intensive care unit. Operative
delivery (vaginal instrumental delivery or caesarean
section) was a secondary outcome. Analysis was by
intention to treat, with confidence intervals calculated for
the differences in percentages or means.
Results 321 pregnant women were randomly allocated to
induction and 329 to expectant monitoring. Induction
group infants were delivered 10 days earlier (mean
difference −9.9 days, 95% CI −11.3 to −8.6) and weighed
130 g less (mean difference −130 g, 95% CI −188 g to
−71 g) than babies in the expectant monitoring group. A
total of 17 (5.3%) infants in the induction group
experienced the composite adverse neonatal outcome,
compared with 20 (61%) in the expectant monitoring
group (difference −0.8%, 95% CI −4.3% to 3.2%).
Caesarean sections were performed on 45 (14.0%)
mothers in the induction group and 45 (13.7%) in the
expectant monitoring group (difference 0.3%, 95% CI
−5.0% to 5.6%).
Conclusions In women with suspected intrauterine
growth restriction at term, we found no important
differences in adverse outcomes between induction of
labour and expectant monitoring. Patients who are keen
on non-intervention can safely choose expectant
management with intensive maternal and fetal
monitoring; however, it is rational to choose induction to
prevent possible neonatal morbidity and stillbirth.
Trial registration International Standard Randomised
Controlled Trial number ISRCTN10363217.
INTRODUCTION
Most infants with intrauterine growth restriction are
born at term.1 Growth restriction so late in gestation
is associated with increased perinatal morbidity in the
form of fetal distress, hypoglycaemia, seizures, beha-
vioural problems, cerebral palsy, and cardiovascular
disease, as well as perinatal mortality.2-11 Obstetricians
often induce labour in cases of intrauterine growth
restriction for fear of neonatal morbidity and later still-
birth. However, observational comparisons of such
infants with matched fetuses delivered after sponta-
neous labour have shown no reduction in short term
adverse neonatal outcomes. Induction might increase
obstetric interventions12-14 and even cause neonatal
morbidity if performed before 39 weeks.15-18 For
these reasons, expectant management with maternal
and fetal monitoring is a commonly followed strategy.
The Disproportionate Intrauterine Growth Inter-
vention Trial At Term (DIGITAT) was designed to
compare the effect of induction of labour with expec-
tant monitoring on a composite adverse neonatal out-
come and on operative delivery rates in infants with
suspected growth restriction beyond 36 weeks’ gesta-
tion. In a pilot trial comparing these two interventions
in 33 women, neonatal outcomes and operative
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delivery rates were comparable, but the precision of
the estimate of the effect size was limited.19
METHODS
The trial was run by theDutchObstetric Consortium, a
collaboration of perinatal centres in the Netherlands,
and approved by the University of Leiden institutional
review board. The study was staffed by obstetricians,
research nurses, and midwives associated with the
Dutch Obstetric Consortium. They counselled and
recruitedparticipants,monitored compliancewith allo-
cated treatment protocols, and collected outcome data.
Recruitment ran from November 2004 to Novem-
ber 2008. The study began in four hospitals, but by
the endof the studyperiod recruitment hadbeen rolled
out to 52 maternity hospitals in Holland. Making the
crude assumptions that the average centre recruited for
half the trial duration of three years (that is, 18months),
that each centre delivered 1500 women a year (adjust-
ing for women seen only in labour or who were ineli-
gible because of multiple pregnancy or breech
pregnancy), and assuming that half of all growth
restricted fetuses are detectable, we anticipated that
about 1326 potentially eligible women would be iden-
tified over the recruitment period.
Participants
Pregnant women between 36+0 and 41+0 weeks’
gestation who had a singleton fetus in cephalic pre-
sentation, suspected intrauterine growth restriction,
and who were under specialised obstetric care were
recruited. Suspected intrauterine growth restriction
was defined as fetal abdominal circumference below
the 10th percentile, estimated fetal weight below the
10th percentile, flattening of the growth curve in the
third trimester (as judged by a clinician), or the pre-
sence of all three factors.20 Both fetuses with abnor-
mal Doppler flow velocity measurements and those
with normal Doppler flow velocity measurements
were included.
The DIGITAT recruitment period overlapped with
recruitment for theHypertension Intervention Trial At
Term (HYPITAT),21 which compared similar inter-
ventions in women with gestational hypertension and
mild pre-eclampsia at term. Patients with both sus-
pected intrauterinegrowth restrictionandhypertension
were preferentially recruited toDIGITAT, andwomen
could not participate in both studies.Gestational hyper-
tension and pre-eclampsia were defined according to
criteria from the International Society for the Study of
Hypertension in Pregnancy.22 Oligohydramnios was
defined as an amniotic fluid index of 5 cm or less.
Exclusion criteria were previous caesarean section,
diabetesmellitus or gestational diabetes requiring insu-
lin therapy, renal failure,HIVseropositivity, prelabour
rupture of membranes, severe pre-eclampsia, HELLP
syndrome (haemolysis, elevated liver enzymes, and
low platelet count), or a fetus with aneuploidy or con-
genital abnormalities suspected on ultrasound. Fetuses
with decreased or absent movements, and those with
abnormal heart rate tracings, were also excluded.
Cervical length was measured using transvaginal
sonography and vaginal digital examination was
performed to assess the Bishop score before
randomisation.23
Randomisation
Participant data were entered into a secure web based
database. Women were randomly allocated to either
induction or expectant monitoring in a 1:1 ratio using
varied sized block randomisation with stratification for
centre and parity (nulliparous or parous women).
Women who declined consent for randomisation but
authorised use of their medical data were treated at the
discretion of the local obstetrician and included in the
database.These datawere used to study external validity
of the trial. Women who refused both randomisation
and collection of identifiable data were registered anon-
ymously. It was not possible to blind participants, obste-
tricians, oroutcomeassessors.Written informedconsent
wasobtained fromall participants before randomisation.
Participants allocated to the induction of labour
group were inducedwithin 48 hours of randomisation.
If theBishop score at randomisationwas greater than6,
labour was induced with amniotomy and, if necessary,
augmentedwith oxytocin.Otherwise cervical ripening
was performed with intracervical or intravaginal pros-
taglandin (E1 or E2 analogue, repeated once after six
hours) or a Foley balloon catheter filled with 30 mL
sodium chloride.24
Participants allocated to the expectant monitoring
group were monitored until the onset of spontaneous
labour with daily fetal movement counts and twice
weekly heart rate tracings, ultrasound examination,
maternal blood pressure measurement, assessment of
proteinuria, laboratory tests of liver and kidney func-
tion, and full blood count. Women were monitored as
either an outpatient or an inpatient, according to local
protocol. In the expectant monitoring group, induc-
tion of labour or planned caesarean section was per-
formed for obstetrical indications—such as
suboptimal fetal heart rate tracings, prolonged rupture
of membranes, or postmaturity between T+7 and T+
14 days—at the obstetrician’s discretion.
Outcomes
The primary outcome was a composite measure of
adverse neonatal outcome. This was defined as death
before hospital discharge, five minute Apgar score of
less than 7, umbilical artery pH of less than 7.05, or
admission to neonatal intensive care. If the umbilical
artery pH data were missing and all other components
of the composite outcome were normal, the neonatal
outcome was classified as normal. Secondary out-
comes were delivery by caesarean section, instrumen-
tal vaginal delivery, length of stay in the neonatal
intensive care or neonatal ward, length of stay in the
maternal hospital, and maternal morbidity. The latter
was defined as postpartum haemorrhage of more than
1000 mL, development of gestational hypertension or
pre-eclampsia (according to International Society for
the Study of Hypertension in Pregnancy criteria),21
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eclampsia, pulmonary oedema, thromboembolism, or
any other serious adverse event.
Study design, sample size, and statistical analysis
The trial was designed as an equivalence trial in which
the null hypothesis was that the difference in the risk of
the composite outcome between the two treatment
groups was greater than 5.5% (absolute percentage).
Assuming that the rate in the control group was 6%
(on the basis of data from the National Dutch Perinatal
Registry25), this meant that we would exclude the null
hypothesis and conclude that the two treatments were
equivalent if the boundaries of the confidence interval
of the observed risk difference were between −5.5%
and 5.5%. With a 0.05 risk of type I error (α) and 80%
(1−β) power, we calculated that we would require 650
participants (325 per group). The sample size formula
for equivalence testing on page 39 of Jones et al26 was
used to calculate these numbers, assuming that the
induction rate and the control rate were both equal to
6% under the alternative of equivalence.
Data were analysed according to the intention to
treat principle. Continuous variables were sum-
marised asmeanswith standard deviations, ormedians
with interquartile ranges (IQR). Treatment effects
were presented as differences in means or percentages
with 95% confidence intervals (CI). Equivalence of the
primary outcome measure was tested by checking if
the 95%CI of the risk difference lay within the equiva-
lence margins. Continuous variables were compared
using the Student’s t test or the non-parametric
Mann-Whitney U test. The χ2 test was used for catego-
rical variables. Instances were more than 5% of the
observations were missing are indicated in the foot-
notes of the tables.
In a secondary analysis, the primary and secondary
outcomes for the two groups were compared after
exclusionofwomenwith hypertension relateddiseases
(pre-existing hypertension, gestational hypertension,
and pre-eclampsia) at randomisation. Given that ran-
domisation was stratified for centre and parity, we also
performed a stratified analysis for the primary out-
come by using logistic regression with parity as fixed
covariate and centre as random covariate. Statistical
analyses were performed using SPSS software (version
16.0; IBM, Chicago, IL) and Stata software (version
10.1; Stata Corp, College Station, TX).
RESULTS
A total of 1116 potentially eligible women were identi-
fied.Of thesewomen, 14 refused anyuse of identifiable
data and452declined randomisation.This left 650par-
ticipants, who were randomly assigned to induction
(n=321) or expectant monitoring (n=329; fig 1). The
baseline characteristics of participants in the two ran-
domised arms and in the non-randomised group are
shown in table 1. Compared with the induction
group, women in the expectant monitoring group
were more likely to have a Bishop score of less than
or equal to 6 and have gestational hypertension, but
otherwise the two randomised arms were comparable.
Women who declined randomisation were older, had
a higher education level, were less likely to smoke, had
a lower bodymass index (BMI), and were less likely to
have a fetal abdominal circumference below the 10th
centile.Most womenwho were randomisedmet either
the fetal abdominal circumference below 10th centile
inclusion criterion or the estimated fetal weight below
the 10th centile criterion.Only 13women in the induc-
tion group and 10 women in the expectant monitoring
group were included because of flattening of the
growth curve in isolation.
Details of the onset of labour are shown in table 2,
and pregnancy outcomes are shown in table 3. Trial
compliance was good, with induction performed in
306 (95.6%) women in the induction group and in
only 166 (50.6%) in the expectant monitoring group,
resulting in amedian time from randomisation to onset
of labour of 0.9 days (IQR 0.7-–1.7) in the induction
group and 10.4 days (IQR 5.6-16.0) in the expectant
monitoring group.
Labour was induced in 166 (50.6%) women in the
expectantmonitoring group: 92 for suspected fetal dis-
tress; 21 for hypertensive disorders; 24 on maternal
request; nine for prelabour rupture of membranes;
five for post-term pregnancy; and 15 for unspecified
maternal reasons. Planned caesarean section was per-
formed in two (0.6%) women in the induction arm: one
because of fetal distress, the second because of primary
genital herpes infection. A total of 11 (3.3%) women in
the expectantmonitoring armhad a planned caesarean
section: in 10 cases for fetal distress and one for unpre-
dicted breech position. In the expectant monitoring
arm, the median time from randomisation to delivery
among women who delivered by planned caesarean
section was 4.5 days. The numbers of operative and
instrumental deliveries were comparable between the
groups (27 (8.4%) in the induction group and 27 (8.2%)
in the expectant monitoring group).
One (0.3%) woman allocated to induction of labour
died at home 10 days after delivery. She had delivered
a healthy child vaginally at 38+4 weeks of gestation
Assigned to expectant monitoring (n=329):
  Induction of labour (n=166)
  Spontaneous onset of labour (n=151)
  Planned caesarean section (n=11)
  Unknown (n=1)
Assigned to induction of labour (n=321):
  Induction of labour (n=306)
  Spontaneous onset of labour (n=12)
  Planned caesarean section (n=2)
  Unknown (n=1)
Women eligible (n=1116)
Women randomised (n=650)
Analysed for primary outcome (n=329)Analysed for primary outcome (n=321)
Excluded (n=466):
  Refused use of medical data (n=14)
  Refused randomisation (n=452):
    Induction of labour (n=88)
    Expectant monitoring (n=364)
Flow diagram of the trial process
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after spontaneous onset of labour. No cause for her
death was found at post mortem and it was classified
as a serious unrelated adverse event. No women in the
expectant monitoring group died during the study.
Neonatal outcomes are shown in table 4. Therewere
no stillbirths or perinatal deaths. A total of 17 (5.3%)
neonates in the induction arm and 20 (6.1%) neonates
in the expectantmonitoring arm had the primary com-
posite adverse neonatal outcome (difference −0.8%,
95% CI −4.3% to 2.8%). No differences between
groups in any of the components of the composite
adverse neonatal outcome were found. Median birth
weight was lower in the induction group than in the
expectant monitoring group (2420 g v 2550 g;
difference −130 g, 95% CI −188 to −71; P<0.001).
Despite this difference, more fetuses in the expectant
monitoring arm had a birth weight below the third per-
centile (100 (31%) v 40 (13%); difference −18.1%, 95%
CI −24.3% to −12.0%; P<0.001).
The numbers of infants admitted to neonatal intensive
care andmedian duration of stay in unit was comparable
between the two groups (9 (2.8%) from the induction
group and 13 (4.0%) in the expectant monitoring group;
duration 9 days, IQR 6–14 and 13 days, IQR 6–22,
respectively). However, more neonates in the induction
groupwere admitted to awardprovidingan intermediate
level of neonatal care (155 (48.4%) v 118 (36.3%); differ-
ence 12.1%, 95% CI 4.6% to 19.7%; P<0.05).
Exclusion of pregnancies complicated by hyperten-
sive disease at randomisation did not alter the results
for the composite adverse neonatal outcome or caesar-
ean section (data not shown). Stratified analysis for cen-
tre and parity using logistic regression showed no
treatment differences among the participating centres
(data not shown).
DISCUSSION
This studyhas shownthat amongwomenwitha singleton
pregnancy complicatedby suspected intrauterine growth
restriction at a gestational age of between 36+0 and 41+
0 weeks, a policy of labour induction affects neither the
rate of adverse neonatal outcomes nor the rates of instru-
mental vaginal delivery or caesarean section.
The present study has only ruled out a difference in
adverse neonatal outcomes larger than 4.3%.We have
not ruled out an effect on the rarer outcomeof perinatal
death.One theoretical argument in favour of induction
is that it might pre-empt intrauterine fetal death, so
clinicians who wish to follow expectant management
should monitor the ongoing pregnancy closely.
In our study the number of admissions to neonatal
intensive care was comparable in both arms, but more
neonates in the induction groupwere admitted to inter-
mediate levels of care. This findingmight be an artefact
Table 1 | Demographic and baseline characteristics of randomised and non-randomised
participants
Induction of labour
group (n=321)
Expectant
monitoring group
(n=329)
Non-randomised
group (n=452)
Nulliparous 182 (56.7) 201 (61.1) 275 (61.0)
Maternal age 27 (23-31) 27 (23-31) 31 (27-34)
BMI at study entry† 22 (20-25) 22 (20-26) 21 (20-24)
Gestational age (days) 263 (258-269) 263 (258-270) 262 (258-269)
White race‡ 254 (83.6) 253 (81.1) 344 (83.3)
Education
Lower professional school 168 (52.3) 170 (51.7) 149 (33.0)
Medium professional school 26 (8.1) 37 (11.2) 93 (20.6)
Unknown 127 (39.6) 122 (37.1) 209 (46.3)
Maternal smoking§ 138 (46.9) 127 (40.8) 114 (26.9)
Blood pressure at booking
Systolic 115 (105-120) 114 (106-120) 115 (110-120)
Diastolic 70 (60-75) 66 (60-75) 70 (60-75)
Gestational hypertension 9 (2.8) 19 (5.8) 25 (5.5)
Pre-eclampsia 18 (5.6) 27 (8.2) 27 (6.0)
Inclusion criteria
Fetal abdominal circumference <10th
percentile
262 (81.6) 270 (82.1) 354 (78.5)
Estimated fetal weight <10th
percentile
296 (92.2) 308 (93.6) 418 (92.5)
Deceleration of fetal abdominal
circumference curve
83 (25.9) 84 (25.5) 95 (21.0)
Fetal abdominal circumference (mm) 287 (278-297) 289 (279-297) 289 (278-299)
Oligohydramnios¶ 87 (31.0) 101 (34.5) 145 (34.4)
Umbilical artery Doppler††
Pulsatility index in the umbilical
artery
0.98 (0.85-1.13) 0.93 (0.82-1.10) 0.96 (0.84-1.11)
Absent 7 (2.7) 7 (2.5) 4 (1.0)
Reversed 0 0 1 (0.2)
Cervical length with transvaginal
sonography (mm) ‡‡
30 (22-37) 30 (24-38) 33 (22-41)
Bishop score ≤6§§ 280 (94.0) 293 (97.3) 64 (98.5)
Table shows median (interquartile range 25th to 75th percentile) or number (%).
†n=275 for induction, n=295 for expectant monitoring, n=364 for non-randomised.
‡n=304 for induction, n=312 for expectant monitoring, n=413 for non-randomised.
§n=294 for induction, n=311 for expectant monitoring, n=424 for non-randomised.
¶n=281 for induction, n=293 for expectant monitoring, n=421 for non-randomised.
††n=262 for induction, n=277 for expectant monitoring, n=381 for non-randomised.
‡‡n=299 for induction, n=312 for expectant monitoring, n=31 for non-randomised.
§§n=298 for induction, n=301 for expectant monitoring, n=65 for non-randomised.
Table 2 | Onset of labour
Induction of
labour group
(n=321)
Expectant
monitoring
group (n=329)
Difference in
mean or
percentage
(95% CI)
Time between
randomisation
and onset of
labour (days)
0.9 (0.7-1.7) 10.4 (5.6-16.0) −9.6 (−10.8 to
−8.5)
Gestational age
at birth (days)
266 (261-271) 277 (269-283) −9.9 (−11.3 to
−8.6)
Onset of labour
Spontaneous 12 (3.7) 151 (46.0) −42.3 (−48.1 to
−36.5)
Planned
caesarean
section
2 (0.6) 11 (3.3) −2.7 (−4.9 to
−0.6)
Induction 306 (95.6) 166 (50.6) 45.0 (39.2 to
50.9)
Table shows median (interquartile range 25th to 75th percentile) or
number (%).
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of the inevitable lower birth weight in this group given
that the policy was to admit infants below a certain
weight, but complications of late prematurity cannot
be ruled out. Limiting induction to infants with a gesta-
tional age of greater than 37 weeks would reduce the
incidence of this outcome, but we cannot know
whether this approach would be associated with better
long term outcomes.27
The higher median birth weight in the expectant
monitoring group indicates that infants in this group
gained on average 130 g during the roughly 10 addi-
tional days’ gestation they experienced comparedwith
the induction group. Presumably, although most neo-
nates in the present trial were bornwith aweight below
the 10th percentile, a number were not really growth
restricted but rather constitutionally small. Constitu-
tionally small infants have the potential to grow at
term, whereas growth restricted infants might experi-
ence intrauterine undernourishment and decelerated
growth. We also observed that the number of children
with a birth weight below the third percentile differed
significantly between the induction of labour group
(12.5%) and the expectant monitoring group (31%).
This suggests that a substantial number of children in
the expectant monitoring group did not continue to
grow along their own expected growth curves. Being
born severely growth restricted appears to be asso-
ciated with worse long term outcomes.27 Although
not defined as a primary outcome in our study, this
suggestion could be a compelling reason for induction
and certainly merits further investigation.
Whenwomenwith hypertension or pre-eclampsia at
the time of randomisation were excluded, the inci-
dence of the composite adverse neonatal outcome
did not differ between the study groups, nor did this
result in a lower incidence of caesarean section
among women in the expectant monitoring group.
Results from the HYPITAT trial support a strategy of
inducing womenwho develop a hypertensive disorder
after 37 weeks of pregnancy to prevent possiblemater-
nal complications.21 This probably also applies to
women who develop hypertensive disorders in addi-
tion to growth restriction, but the number of such
women in this trial was too small to investigate this
possibility in detail.
Table 3 | Pregnancy outcomes
Induction of labour
group (n=321)
Expectant
monitoring group
(n=329)
Difference in mean or
percentage (95% CI)
Mode of delivery
Spontaneous vaginal delivery 249 (77.6) 257 (78.1) −0.5 (−6.9 to 5.8)
Vaginal instrumental 27 (8.4) 27 (8.2) 0.2 (−4.0 to 4.4)
Caesarean section 45 (14.0) 45 (13.7) 0.3 (−5.0 to 5.6)
Indications for caesarean section
Suspected fetal distress (with or
without arrest of labour)
37 (82.2) 40 (88.9) −6.7 (−21.1 to 7.8)
Arrest of labour 5 (11.1) 2 (4.4) 6.7 (−4.3 to 17.6)
Other 3 (6.7) 3 (6.7) 0.0 (−10.3 to 10.3)
Indications for instrumental vaginal delivery
Suspected fetal distress (+/− arrest
of labour)
21 (77.8) 25 (92.6) −14.8 (−33.3 to 3.7)
Arrest of labour 6 (22.2) 2 (7.4) 14.8 (−3.7 to 33.3)
Adverse maternal outcome
Maternal death 1 (0.3) 0 NA
Progression to gestational
hypertension
1 (0.3) 6 (1.8) −1.5 (−3.1 to 0.1)
Progression to pre-eclampsia 12 (3.7) 26 (7.9) −4.2 (−7.7 to −0.6)*
Eclampsia, lung oedema,
thromboembolic events
0 0 NA
Abruption placentae (partial) 1 (0.3) 0 NA
Postpartum haemorrhage 10 (3.2) 15 (4.7) −1.5 (−4.5 to 1.5)
Maternal admission (days)†
Length of stay in hospital 4 (2-6) 4 (2-7) **
Table shows median (IQR 25th to 75th percentile) or number (%).
*P<0.05; **P=0.2 (Mann-Whitney test).
†n=232 admitted for induction, n=242 admitted for expectant monitoring. NA=not applicable.
Table 4 | Neonatal outcomes
Inductionof
labour
group
(n=321)
Expectant
monitoring
group
(n=329)
Difference in
mean or
percentage
(95% CI)
Birth weight (g) 2420(2220–
2660)
2550(2255–
2850)
−130 (−188 to
−71)**
Birthweight
percentiles†
<Third percentile 40 (12.5) 100 (30.6) −18.1 (−24.3 to
−12.0)**
Third to fifth
percentile
82 (25.5) 79 (24.2) 1.3 (−5.3 to 8.0)
Fifth to 10th
percentile
88 (27.4) 62 (18.9) 8.5 (−2.0to14.9)
10th to 25th
percentile
88 (27.4) 66 (20.2) 7.2 (0.7 to 13.8)
>25th percentile 23 (7.2) 20 (6.1) −1.1 (−2.8 to4.9)
Composite adverse
neonatal outcome
17 (5.3) 20 (6.1) −0.8 (−4.3 to2.8)
Fetal deaths 0 0 —
Neonatal deaths 0 0 —
Apgar score after five
minutes <7
7 (2.2) 2 (0.6) 1.6 (−0.2 to 3.4)
Arterial pH <7.15‡ 34 (12.2) 38 (13.2) −1.0 (−6.5 to4.5)
Arterial pH <7.10‡ 12 (4.3) 19 (6.6) −2.3 (−6.0 to1.4)
Arterial pH <7.05‡ 4 (1.4) 10 (3.5) −2.1 (−4.6 to0.5)
Arterial baseexcess <
−10‡
16 (5.7) 26 (9.0) −3.3 (−7.6 to1.0)
Admission to
intensive care
9 (2.8) 13 (4.0) −1.2 (−4.0 to1.6)
Neonatal admission
Intermediate care 155 (48.4) 118 (36.3) 12.1(4.6to19.7)
*
Maternal ward 89 (27.8) 116 (35.7) −7.9 (−15.0 to
−0.7)*
No admission 67 (20.9) 78 (24.0) −3.1 (−9.5 to3.4)
Length of stay (days)
Infants in the
neonatal intensive care
unit
9 (6-14) 13 (6-22) ***
All admissions 4 (2-8) 4 (2-8) 0.2 (−1.4 to 1.8)
Table shows median (IQR 25th to 75th percentile) or number (%).
*P<0.05; **P<0.001; ***P=0.2 (Mann-Whitney test).
†Percentiles according to Dutch fetal growth charts (weight related to
gestational age).36
‡n=279 for induction, n=288 for expectant monitoring.
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Comparison with other studies
Previous observational studies suggest that antenatal
detection and induction are associated with an increased
incidence of obstetric interventions, without a demon-
strable neonatal benefit.12-14 However, our finding of no
effect of induction on adverse neonatal outcomes, which
is froma randomised trial, should supersede findings from
observational studies. The finding that induction did not
affect the rate of operative deliveries in our study should
also not be surprising because observational studies that
suggestedan increase inoperative interventionwith induc-
tion have been contradicted by later randomised trials.
Observational studies of the effect of induction near term
forother fetal indications—suchaspost-maturity, ruptured
membranes, and hypertensive disease—on the rate of
operative deliveries have been similarly misleading.2829
A similar trial of timed delivery among much more
severely compromised pre-term fetuses, the Growth
Restriction Intervention Trial (GRIT), was reported in
2004.30 31 At two year follow-up, the risk of disability
was reduced in the delayed delivery group compared
with the immediate delivery group among babies
younger than 31 weeks of gestation at randomisation.
Because growth restriction is associated with a less
favourable neurodevelopmental outcome in the term
period as well as poor outcomes at delivery,32 we plan
to investigate thewellbeing of the children randomised
during DIGITAT at two year follow-up.
Strengths and limitations of study
The main strength of this study is the comparison of
randomised groups and the large size of the study
population. There have been no other randomised
trials in this area.
Identifying fetuses at risk of true intrauterine growth
restriction is a diagnostic challenge. Customised
growth centile charts33 are rarely applied in theNether-
lands andwere not used in the present study, butmight
identify fetuses at risk. Although we encountered no
perinatal deaths among the randomised women, the
association between low birth weight and perinatal
death is well accepted.1-4 However, many thousands
of participants would be required to power a study on
the effects of induction on perinatal death.
The relatively favourable neonatal outcomes in both
study groups could reflect the fact that participants and
clinicians were more alert to possible complications and
women received cautious attention from their doctors.
Monitoring is also intensified in ordinary practice in the
Netherlands, but monitoring and therefore neonatal out-
comes could have been biased because of the study set-
ting.Thestudyresults shouldbeextrapolatedwithcaution
to settings where close monitoring cannot be offered.
It was possible to defer delivery in the expectant
monitoring group for on average 9.6 days after rando-
misation, resulting in an average gestational age of 39+
3 weeks. Prolongation of gestational age in this group
led to more instances of spontaneous vaginal delivery
than in the induction group, but did not reduce the
number of caesarean sections. Compared with other
countries (that is, the United States and the United
Kingdom), rates of caesarean section in the Nether-
lands have always been relatively low,34 and the rate
in this group of high risk pregnancies was even lower
than the average rate of 15% in the Netherlands.25
The fact that women who declined randomisation
were older, more highly educated, and smoked less
might suggest that the study recruited a slightly biased
group of women. This may have an effect on the gen-
eralisability of the results.
Conclusions and policy implications
In conclusion, we found equivalent fetal and maternal
outcomes for induction and expectant monitoring in
women with suspected intrauterine growth restriction at
term, indicating that both approaches are acceptable. In
practice, however, obstetricians and patients will let fac-
tors other than growth restriction guide decisionmaking
at delivery.35 It is reasonable for patientswho are keenon
non-intervention to choose expectant management with
intensivematernal and fetalmonitoringbecause, as far as
we can tell, this approach is safe for the baby.However, it
is more rational to choose induction to prevent possible
neonatal morbidity and stillbirth on the grounds that we
showed no increase in operative and instrumental deliv-
ery rates. However, our study was underpowered to
show differences in late pregnancy loss.
By inducing labour in cases of intrauterine growth
restriction, infants who will not grow any further can
be released from their undernourished environment.
Future studies should focusonhow todistinguishbefore
childbirth fetuses with genuine growth restriction and
those that are constitutionally small, and on elucidating
which antepartum factors predict adverse outcomes.
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